Bafna Pharmaceuticals Limited (IN:BAFNAPH)
:BAFNAPH
Want to see IN:BAFNAPH full AI Analyst Report?
BAFNAPH Stock Chart & Stats
₹154.65
-₹1.34(-1.60%)
At close: 4:00 PM EST
₹154.65
-₹1.34(-1.60%)
Day’s Range― - ―
52-Week Range₹71.65 - ₹204.95
Previous CloseN/A
Volume2.58K
Average Volume (3M)1.19K
Market Cap
₹3.34B
Enterprise Value₹3.47B
Total Cash (Recent Filing)₹19.67M
Total Debt (Recent Filing)₹324.03M
Price to Earnings (P/E)48.5
Beta0.66
Next Earnings
Jun 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.78
Shares Outstanding23,656,336
10 Day Avg. Volume1,123
30 Day Avg. Volume1,187
Financial Highlights & Ratios
PEG Ratio-0.98
Price to Book (P/B)2.09
Price to Sales (P/S)1.22
P/FCF Ratio-76.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Multi-year Revenue GrowthSustained multi-year revenue expansion indicates durable demand for the company’s generics and successful market penetration. This scale supports fixed-cost absorption, distribution leverage and a stronger platform for new product introductions, underpinning growth resilience over the next 2–6 months and beyond.
Stable Equity Base And Manageable LeverageA sound equity base and moderate debt levels provide financial flexibility for regulatory compliance, capacity investment and working capital needs. This balance sheet strength reduces refinancing risk and supports continued operations and strategic spending under normal market conditions.
Diversified Manufacturing And Sales ChannelsOwning manufacturing and selling both domestically and via exports provides diversified revenue sources and control over production quality and costs. This vertical integration and multi-market exposure reduces single-market dependency and supports more durable cashflows across regulatory and demand cycles.
Bears Say
Profitability CompressionFalling gross and net margins signal pressure on pricing, input costs or product mix, eroding earnings quality. Margin compression reduces internal funding for R&D, compliance and capex, making the business more sensitive to cost shocks and limiting durable free-cash generation.
Volatile Free Cash FlowPersistent FCF volatility and recent negative trends weaken the company's ability to self-fund investments, repay debt or build reserves. This instability raises the probability of needing external financing for capex or working capital, which can increase long-term funding costs and operational risk.
Slightly Increased Leverage RiskA declining equity ratio implies reduced buffer against shocks and less headroom for additional borrowing. Coupled with margin pressure, higher leverage can constrain strategic investments, heighten solvency risk in downturns and limit the firm's ability to respond to regulatory or market changes.
Bafna Pharmaceuticals Limited News
BAFNAPH FAQ
What was Bafna Pharmaceuticals Limited’s price range in the past 12 months?
Bafna Pharmaceuticals Limited lowest stock price was ₹71.65 and its highest was ₹204.95 in the past 12 months.
What is Bafna Pharmaceuticals Limited’s market cap?
Bafna Pharmaceuticals Limited’s market cap is ₹3.34B.
When is Bafna Pharmaceuticals Limited’s upcoming earnings report date?
Bafna Pharmaceuticals Limited’s upcoming earnings report date is Jun 03, 2026 which is in 35 days.
How were Bafna Pharmaceuticals Limited’s earnings last quarter?
Bafna Pharmaceuticals Limited released its earnings results on Feb 11, 2026. The company reported ₹0.776 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.776.
Is Bafna Pharmaceuticals Limited overvalued?
According to Wall Street analysts Bafna Pharmaceuticals Limited’s price is currently Overvalued.
Does Bafna Pharmaceuticals Limited pay dividends?
Bafna Pharmaceuticals Limited pays a Notavailable dividend of ₹0.6 which represents an annual dividend yield of N/A. See more information on Bafna Pharmaceuticals Limited dividends here
What is Bafna Pharmaceuticals Limited’s EPS estimate?
Bafna Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bafna Pharmaceuticals Limited have?
Bafna Pharmaceuticals Limited has 23,656,336 shares outstanding.
What happened to Bafna Pharmaceuticals Limited’s price movement after its last earnings report?
Bafna Pharmaceuticals Limited reported an EPS of ₹0.776 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.563%.
Which hedge fund is a major shareholder of Bafna Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in IN:BAFNAPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bafna Pharmaceuticals Limited
Bafna Pharmaceuticals Limited manufactures and sells finished pharmaceutical formulations in India. The company provides delayed and sustained release, chewable, and orally disintegrating tablets. It also exports its products. Bafna Pharmaceuticals Limited was founded in 1981 and is based in Chennai, India.
Technical Analysis
Aarey Drugs & Pharmaceuticals Ltd.
―
Alpa Laboratories Limited
―
Bal Pharma Limited
―
Krebs Biochemicals & Industries Ltd.
―
Mangalam Drugs & Organics Ltd.
―